Launch of Advanced Epilepsy Monitoring System Generating Increased Demand;
                  Supports Favorable Outlook for Fiscal 2000

    MUNDELEIN, Ill., May 20 /PRNewswire/ -- Bio-logic Systems Corp.
(Nasdaq: BLSC), a designer and marketer of computerized medical
electrodiagnostic equipment, today reported results for its fourth quarter and
fiscal year ended February 28, 1999.
    Dr. Gabriel Raviv, president and chief executive officer, stated, "Fiscal
1999 was a difficult year for us as we saw total sales decrease to
$17.4 million from $18.0 million last year and net income decrease to $290,000
or $0.07 per share from $1.1 million or $0.28 per share a year ago.  While
U.S. sales increased 7 percent compared with last year, international sales
were hard hit by the Asian economic crisis, decreasing 41 percent from a
year ago, when more than 21 percent of our sales came from overseas, to
$2.3 million representing only 13 percent of sales in fiscal 1999."
    "Despite a challenging operating environment internationally, the company
remained focused on its goals and we believe our perseverance is beginning to
pay off," said Dr. Raviv.  "In the fourth quarter we recorded an increase in
sales as demand for our Ceegraph products accelerated with the roll out of
upgraded software packages.  Further, the introduction of our 64/128 channel
Ceegraph XL, the most advanced monitoring system for epilepsy, is generating
larger orders and, since only a few competitors offer this technology, we're
leveraging our full-systems capabilities to capture a greater share of the
$20 million epilepsy market."
    Sales for the fiscal 1999 fourth quarter were $5.0 million compared with
$4.7 million in the similar fiscal 1998 quarter.  Domestic sales rose 31
percent, while international sales declined 67 percent from a year earlier.
Net income was $389,872, or $0.10 per share, compared with $354,335, or
$0.09 per share, a year ago.  The 10 percent increase in net income was
primarily attributable to stronger sales, only a modest increase in operating
expenses and a substantial reduction in the company's provision for income
taxes related to differences in the consolidated tax rates between Bio-logic
in the U.S. and the company's foreign subsidiary in Israel.
    Dr. Raviv continued, "During fiscal 1999, we were entrenched in research
and development initiatives, and converting all of our software programs.  We
continue to communicate regularly with our international customers and are
beginning to see a resurgence in interest for our modular systems and new
technologies.  The international marketplace remains an important source of
growth for us and we hope to begin recovering those sales by the end of our
fiscal year, next February."

    Fiscal 2000 Outlook Favorable
    Bio-logic has two new products that are winning strong demand in the
epilepsy market.  Its Ceegraph XL 64/128 channel monitoring system and a
digital video monitor are generating large orders from major hospitals and
epilepsy centers around the world.  An increasing number of epilepsy
specialists are viewing 64-channel systems as the benchmark for quality
testing.  Bio-logic is one of only a few manufacturers able to compete for
this business from the nearly 2,000 buyers in the U.S.  In the second half of
fiscal 1999, the company was awarded a $1.4 million contract from Boston
Children's Hospital for Bio-logic's complete neurodiagnostic system.
Contracts like this are being driven by a company's ability to offer the more
advanced monitoring and can result in the purchase of a full product line of
complementary modules, as was the case with Boston Children's.
    "We believe the availability of our Windows software for our Ceegraph
system and the launch of Ceegraph XL and digital video modules will drive
important top-line growth this year.  Compared with the size of traditional
orders, orders that include Ceegraph XL are much larger.  We are already
experiencing strong demand and good order rates for these products and
therefore, are very optimistic about our operating performance for the first
half of the fiscal year."
    Bio-logic's AuDX(R) system continues to drive sales of its audiology line.
AuDX, a hearing screening device for infants, children and adults that
encourages regular testing and supports early detection, is targeted at the
large pediatrician and general practitioner market as well as audiologists.
Legislation for mandatory hearing screening is increasing and many hospitals
are required to be in compliance by July 2000.  With this date approaching and
the pediatrician base growing, sales of AuDX are expected to ramp up
significantly this year.
    Finally, the company's Sleepscan products should contribute greater to
total sales once the Windows upgrade on that system is completed in the second
quarter.
    "Fiscal 2000 should reflect not only modest recovery internationally, but
strong growth in North America.  And even if the international market remains
closed, our new products and expanding capabilities should substantially
improve our domestic business.  All expenses related to the software
conversion and ISO 9000 certification are behind us.  We believe we've turned
a corner and are now positioned to capitalize on our unrivaled technology,
strong understanding of the markets we serve, and comprehensive systems and
support," said Dr. Raviv.

    Liquid Balance Sheet with Low Leverage
    The company's cash and marketable securities increased to $6.0 million at
February 28, 1999 from $5.1 million a year earlier.  Long-term debt as a
percent of capitalization decreased to 2.3 percent, and the current ratio was
4.8 to 1.  Shareholders' equity increased to $12.7 million from $12.4 million
at February 28, 1998.
    Bio-logic Systems Corp., headquartered in Mundelein, Ill., designs,
develops, assembles and markets computer-based electrodiagnostic systems for
use by hospitals, clinics, universities and physicians.  The systems conduct
tests that are typically used by medical practitioners to aid in the diagnosis
of certain neurological, psychiatric and sensory disorders, psychological and
learning disorders, brain disorders and tumors.

    Safe Harbor Statement
    Except for descriptions of historical facts, this release contains
forward-looking statements that involve known and unknown risks, which may
cause the company's actual results in the future to differ materially from
those currently anticipated.  These risks include, among others, fluctuations
in sales and operating results; risks associated with international operations
including monetary crisis; regulatory, competitive, and contractual risks; the
effects of economic conditions; any delays or additional costs associated with
the marketing of the AuDX(R) product; and the availability of capital to
finance planned growth, as well as other risks detailed from time to time in
the company's filings with the Securities and Exchange Commission.


                     BIO-LOGIC SYSTEMS CORP. AND SUBSIDIARIES
                      CONSOLIDATED STATEMENTS OF OPERATIONS
                     Periods Ended February 28, 1999 and 1998
                                   (Unaudited)

                                      Year Ended           Three Months Ended
                                  1999          1998       1999       1998
    NET SALES                 $17,418,286 $18,018,689  $4,969,004 $4,714,178
    COST OF SALES               5,633,758   5,703,652   1,684,004  1,445,172

    Gross profit               11,784,528  12,315,037   3,285,000  3,269,006

    OPERATING EXPENSES:
      Selling, general, and
        administrative          8,831,053   8,347,149   2,248,313  2,154,122
      Research and development  2,854,105   2,416,774     613,044    606,814

        Total operating
          expenses             11,685,158  10,763,923   2,861,357  2,760,936

    OPERATING INCOME               99,370   1,551,114     423,643    508,070

    OTHER INCOME (EXPENSE):
      Interest income             258,558     219,285      60,242     62,914
      Interest expense            (31,525)    (45,780)     (7,868)   (13,481)
      Miscellaneous                (3,704)       (633)     (2,061)    (3,177)

    TOTAL OTHER INCOME            223,329     172,872      50,313     46,256

    INCOME BEFORE INCOME TAXES    322,699   1,723,986     473,956    554,326

    PROVISION FOR INCOME TAXES     33,559     575,550      84,084    199,987

    NET INCOME                   $289,140  $1,148,436    $389,872   $354,339

    NET INCOME PER SHARE:
      Basic                         $0.07       $0.29       $0.10      $0.09
      Diluted                       $0.07       $0.28       $0.10      $0.09

    AVERAGE NUMBER OF SHARES
      OUTSTANDING
      Basic                     4,008,201   3,959,864   4,005,492  3,982,480
      Diluted                   4,095,939   4,117,334   4,042,854  4,151,299

                           SELECTED BALANCE SHEET DATA

                                                 1999                1998
    Cash and marketable securities           $5,957,112          $5,124,467
    Current assets                           13,385,871          12,882,143
    Total assets                             16,038,207          15,801,237
    Current liabilities                       2,793,361           2,645,722
    Net Shareholders' equity                 12,705,333          12,434,793

Link to this page: